Procos, a CDMO of active pharmaceutical ingredients (APIs), high-potency active pharmaceutical ingredients (HPAPIs), and advanced intemediates, is expanding small-molecule API manufacturing. David Short, Senior Manager Business Development, Custom Synthesis, Procos, highlighted the company’s expansion at the DCAT Member Company Forum at DCAT Week.  

A key pillar of our continued expansion is the company’s R11 manufacturing facility in Cameri, Italy. With its building shell complete and equipment installation underway, R11 will feature 20 reactors across four multi-purpose production lines, offering capacities from 1,000 to 6,000 liters. This expansion adds 73 cubic meters to existing production capacity to address demand for high-value, complex small-molecule drug substances, particularly in clinical development. 

Scheduled for full qualification in 2025, the R11 facility will boost Procos’ overall manufacturing capacity by 25%. It will provide flexible mid-scale production for specialized therapeutics and smaller volumes.